NASDAQ:ZEAL
Delisted

Zealand Pharma Stock News

etoro logo Buy ZEAL
*Your capital is at risk
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering ​its push to take on market lead
Press release – No. 13 / 2026  New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight m
Press release – No. 12 / 2026 Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference Copenhagen, Denmark, June 2, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Company announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand
Company announcement – No. 19 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Press release – No. 10 / 2026 Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as eP
Company announcement No. 18 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 21, 2026) Copenhagen, Denmark, May 26, 2026 – Zealand Pharma A/S ("the Company" or “Zealand
Company announcement – No. 17 / 2026 Resolutions from Zealand Pharma's Extraordinary General Meeting 2026 Copenhagen, Denmark, May 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company�
Company announcement No. 16 / 2026 Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026) Copenhagen, Denmark, May 14, 2026 – Zealand Pharma A/S ("the Company" or “Zea
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasd
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, pe
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Fin
Press release - No. 9 / 2026 The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting Camilla Sylvest will bring d
Company announcement – No. 12 / 2026 Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026 Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE